Today: 19 April 2026
Diageo share price slips as traders eye Feb 25 results and CEO’s next move
6 February 2026
1 min read

Diageo share price slips as traders eye Feb 25 results and CEO’s next move

London, Feb 6, 2026, 09:35 GMT — Regular session

  • Diageo shares dipped roughly 1.5% in early London trading, erasing some of the gains posted earlier this week.
  • Investors are eyeing the company’s Feb 25 interim results for clues on demand trends and any updated guidance.
  • The stock has plunged over the past year following a harsh downgrade to its outlook.

Diageo (DGE.L) shares dropped 1.5%, hitting 1,760.5 pence by 0935 GMT. The stock opened at 1,775 pence and fluctuated between 1,745.5 and 1,784.7 in early trading. Around 587,000 shares exchanged hands. Over the past year, the shares have slid about 22%.

The retreat came after a rapid rebound earlier this week: Diageo climbed 0.7% on Thursday, stepping back from a 4.5% surge Wednesday. Both days saw hefty trading volumes, just over 5 million shares each, according to Investing.com’s data.

The key date to watch is the calendar. Diageo will release its interim results on Feb. 25, starting with a webcast at 0705 UK time featuring Chief Executive Sir Dave Lewis and CFO Nik Jhangiani. A live Q&A session follows at 0930.

Friday saw little support from the broader market. European shares edged lower, with the STOXX 600 falling 0.2% as investors digested mixed earnings and renewed jitters in tech stocks.

In the UK, the Bank of England’s surprise 5-4 decision to keep rates at 3.75% on Thursday set the tone, dragging the pound down and fueling speculation about rate cuts later this year.

Diageo faces its own set of strategic questions. A Reuters Breakingviews column this week suggested Lewis might consider offloading assets in China, pointing to a nearly $2 billion stake in a spirits maker that’s underperforming but still seen as “prized.” Breakingviews

The market remains weighed down by last year’s guidance reset. In November, Diageo slashed its annual forecast, warning fiscal 2026 sales would be flat or dip slightly, hit by weaker demand in the US and China. “Whether a new CEO has a different view and a different strategy, no one will know until a permanent CEO is in place,” Richard Scrope, manager of the VT Tyndall Global Select Fund, told Reuters back then. Reuters

The risk factors remain. When Diageo brought in Lewis — Tesco’s ex-boss known for trimming costs — Reuters noted the company faced U.S. tariff challenges, heavy debt, and changing drinking trends among younger buyers; RBC Capital Markets analyst James Edwardes Jones described the hire as a “pleasant surprise” in a note. Reuters

All eyes are on Feb. 25, when the half-year results drop. Traders will be scanning for shifts in the company’s fiscal 2026 outlook, early signals on U.S. spirits demand, trends out of China, and how fast the new leadership aims to tackle costs and portfolio sales.

Stock Market Today

  • Nordea Bank Abp's Mixed Share Performance and Valuation Analysis
    April 18, 2026, 10:42 PM EDT. Nordea Bank Abp (HLSE:NDA FI) exhibits mixed returns with a negative year-to-date but a 51.1% total return over one year, showing strong long-term momentum. The bank's share price closed at €16.02, slightly below the €16.55 analyst target and a fair value estimate of €17.03, suggesting it may be undervalued. Nordea is investing heavily in digital technologies and cybersecurity, aiming to improve net margins and fee income. However, potential risks include Nordic housing market weakness and rising regulatory costs. Investors are advised to weigh both upside potential and downside risks before making decisions, considering broader financial sector comparisons and market conditions.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Compass Group share price slips again as AI fears linger after Q1 update
Previous Story

Compass Group share price slips again as AI fears linger after Q1 update

Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan
Next Story

Molina Healthcare stock sinks premarket after 2026 outlook miss, Medicare exit plan

Go toTop